Archive · 12 Nov 2025
Natco Pharma Completes Delisting of Adcock Ingram from Johannesburg Stock Exchange
A company called Natco Pharma bought a big part of another South African company called Adcock Ingram.
Adcock Ingram is a very old company that makes medicines and has been around for a long time.
Because Natco Pharma now owns a lot of Adcock Ingram, they were able to take it off the big stock market in South Africa.
This is part of Natco Pharma's plan to grow its business in Africa.
They want to use Adcock Ingram's good reputation to sell more of their medicines.
Adcock Ingram has famous brands that people in South Africa trust.
Natco Pharma has finalized the delisting of Adcock Ingram Holdings from the Johannesburg Stock Exchange on November 11, 2025.
This follows Natco Pharma's acquisition of a 35.75% stake in Adcock Ingram for approximately US$226 million (ZAR 4 billion).
The acquisition is a strategic move for Natco Pharma's global growth and aims to enhance Adcock Ingram's capabilities.
Adcock Ingram, founded in 1891, is a long-standing pharmaceutical company in South Africa known for brands like Panado and Allergex.
Natco Pharma offered ZAR 75 per share to minority shareholders in July 2025, which was approved in October 2025, securing its market presence.
- Who
- Natco Pharma
- What
- Completed the delisting of Adcock Ingram Holdings Ltd from the Johannesburg Stock Exchange after acquiring a 35.75% stake.
- When
- Delisting completed as of November 11, 2025.
- Where
- Johannesburg Stock Exchange (JSE)
- Why
- As part of Natco Pharma's global growth plans to expand its market presence in South Africa and beyond, leveraging Adcock Ingram's established position and consumer trust.
- Acquiring Company
- Natco Pharma
- Acquired Company
- Adcock Ingram Holdings Ltd
- Acquisition Stake
- 35.75%
- Transaction Value
- US$226 million (ZAR 4 billion)
- Delisting Date
- November 11, 2025
- Offer Price Per Share
- ZAR 75 ($4.36)